Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 17/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24285827 | 1.00 | KRAS (0.51) | KRASABL1MAP4K1 | |
| SCHEMBL29445310 | 0.95 | KRAS (0.49) | KRASABL1MAP4K1 | |
| SCHEMBL24285741 | 0.95 | KRAS (0.49) | KRASABL1MAP4K1 | |
| SCHEMBL20444852 | 0.91 | KRAS (0.51) | KRASABL1 | |
| SCHEMBL29445213 | 0.89 | KRAS (0.51) | KRASABL1 | |
| SCHEMBL24285776 | 0.89 | KRAS (0.51) | KRASABL1 | |
| SCHEMBL29445306 | 0.86 | KRAS (0.50) | KRASABL1MAP4K1 | |
| SCHEMBL20445005 | 0.86 | KRAS (0.50) | KRASABL1MAP4K1 | |
| SCHEMBL24285829 | 0.86 | KRAS (0.50) | KRASABL1 | |
| SCHEMBL20444973 | 0.84 | KRAS (0.51) | KRASABL1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | KRAS 1/4885ABL1 63/4885MAP4K1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.